PMID- 29134607
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 9
IP  - 1
DP  - 2018 Feb
TI  - The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment 
      of Patients with Type 2 Diabetes Mellitus in France.
PG  - 13-25
LID - 10.1007/s13300-017-0321-0 [doi]
AB  - INTRODUCTION: Dulaglutide is a novel onceweekly administered glucagon-like 
      peptide 1 receptor agonist (GLP-1 RA) for the management of type 2 diabetes 
      mellitus (T2DM). The objective of this analysis was to estimate the 
      cost-effectiveness of dulaglutide 1.5 mg versus exenatide QW for the management 
      of T2DM in France. METHODS: The QuintilesIMS CORE Diabetes Model was used to 
      estimate the expected lifetime direct medical costs and outcomes of T2DM from the 
      perspective of the French National Health Service. In the absence of head-to-head 
      data, relative efficacy was derived from a network meta-analysis. Patient cohort 
      characteristics were derived from the AWARD-2 trial. All patients were assumed to 
      remain on treatment for 2 years before escalating to insulin therapy. Costs 
      included treatment costs and costs associated with long-term complications of 
      T2DM. Utilities were estimated based on a recent systematic review. One-way 
      sensitivity analyses (OWSA) and probabilistic sensitivity analysis (PSA) were 
      conducted. Cost-effectiveness acceptability curves (CEACs) were generated. 
      RESULTS: Dulaglutide 1.5 mg was associated with lower costs (lifetime costs 
      euro41,562 vs euro43,021) and increased health benefits (lifetime quality-adjusted life 
      years: QALYs 9.804 vs 9.757) versus exenatide QW for the treatment of T2DM in 
      France. OWSA and PSA indicated that results were robust across a range of 
      plausible input parameters. The CEAC indicated a 99.5% probability that 
      dulaglutide would be considered cost-effective at a willingness to pay of 
      euro30,000. CONCLUSION: Dulaglutide 1.5 mg reduced expected costs and increased 
      expected QALYs when compared against exenatide QW for the treatment of T2DM in 
      France. Compared with exenatide QW, dulaglutide 1.5 mg can provide additional 
      health benefits for patients with T2DM and may result in cost savings for payers. 
      FUNDING: Eli Lilly.
FAU - Basson, Mickael
AU  - Basson M
AD  - Eli Lilly, Neuilly-sur-Seine, France.
FAU - Ntais, Dionysios
AU  - Ntais D
AD  - QuintilesIMS, London, UK.
FAU - Ayyub, Ruba
AU  - Ayyub R
AD  - QuintilesIMS, London, UK.
FAU - Wright, Donna
AU  - Wright D
AD  - QuintilesIMS, London, UK.
FAU - Lowin, Julia
AU  - Lowin J
AD  - QuintilesIMS, London, UK.
FAU - Chartier, Florence
AU  - Chartier F
AD  - Eli Lilly, Neuilly-sur-Seine, France.
FAU - Roze, Stephane
AU  - Roze S
AD  - HEVA-HEOR, Lyon, France.
FAU - Norrbacka, Kirsi
AU  - Norrbacka K
AD  - , Helsinki, Finland. norrbacka_kirsi@lilly.com.
LA  - eng
PT  - Journal Article
DEP - 20171113
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC5801216
OTO - NOTNLM
OT  - Cost-utility
OT  - Dulaglutide
OT  - Exenatide QW
OT  - France
OT  - Type 2 diabetes
EDAT- 2017/11/15 06:00
MHDA- 2017/11/15 06:01
PMCR- 2017/11/13
CRDT- 2017/11/15 06:00
PHST- 2017/07/14 00:00 [received]
PHST- 2017/11/15 06:00 [pubmed]
PHST- 2017/11/15 06:01 [medline]
PHST- 2017/11/15 06:00 [entrez]
PHST- 2017/11/13 00:00 [pmc-release]
AID - 10.1007/s13300-017-0321-0 [pii]
AID - 321 [pii]
AID - 10.1007/s13300-017-0321-0 [doi]
PST - ppublish
SO  - Diabetes Ther. 2018 Feb;9(1):13-25. doi: 10.1007/s13300-017-0321-0. Epub 2017 Nov 
      13.